Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 617282, 6 pages
Research Article

Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters

1Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Stomatology, Union Hospital, Huazhong University of Science and Technology, Wuhan 430022, China

Received 12 October 2014; Revised 14 December 2014; Accepted 28 December 2014

Academic Editor: James C. C. Wei

Copyright © 2015 Rongfen Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Soluble CD30 (sCD30), a transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily, has been shown to be associated with various pathological conditions. This study was designed to measure the levels of serum sCD30 in patients with ankylosing spondylitis (AS) and to evaluate the relationships between serum sCD30 levels and other disease severity-related indexes, including bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS), and bath ankylosing spondylitis functional index (BASFI). Our results demonstrated significantly elevated sCD30 levels in AS patients compared to healthy controls (HCs) with mean values of and  ng/mL, respectively , suggesting a potential role of sCD30 in the pathogenesis of AS. However, no significant correlations of sCD30 with BASDAI, ASDAS, or BASFI were detected in our study . Therefore, sCD30 cannot be used as a reliable marker for reflecting disease activity and functional ability of AS patients.